NCT04721223 - JAB-3068 Activity in Adult Patients With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 26, 2021

Primary Completion Date

December 29, 2023

Study Completion Date

December 29, 2023

Conditions

Advanced Solid TumorEsophageal Squamous Cell CarcinomaNon Small Cell Lung CancerHead and Neck Squamous Cell Carcinoma

Interventions

DRUG

JAB-3068

JAB-3068 administrated orally as a tablet.

DRUG

PD1 inhibitor

JS001 administrated as an intravenous(IV) infusion.

Trial Locations (3)

Beijing Cancer Hospital, Beijing

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

Henan Cancer Hospital, Zhengzhou